NCT04165590View on ClinicalTrials.gov

Plasmodium Immunotherapy for Advanced Malignant Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

October 31, 2026

Conditions
Advanced Malignant Solid Tumor
Interventions
OTHER

Plasmodium immunotherapy

The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10\^7 Plasmodium parasites.

Trial Locations (1)

650000

RECRUITING

Yunnan Kungang Hospital, Kunming

All Listed Sponsors
lead

CAS Lamvac Biotech Co., Ltd.

INDUSTRY